Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.
about
Toxic epidermal necrolysis and Stevens-Johnson syndromeDrug induced exfoliative dermatitis: state of the artNew genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivityIdiosyncratic adverse drug reactions: current conceptsHarvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactomeReview of Toxic Epidermal NecrolysisSevere desquamating disorder after liver transplant: toxic epidermal necrolysis or graft versus host disease?Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain long-lived IFN-γ and sFasL memory responseThe association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population.Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk.HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactionsThe current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis.Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies.Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome.Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.A marker for Stevens-Johnson syndrome ...: ethnicity matters.[Toxic epidermal necrolysis induced by phenobarbital in a Rwandan child: report of a case].Immunological principles of T-cell-mediated adverse drug reactions in skin.Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of ChinaDrug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis.Role of bioactivation in drug-induced hypersensitivity reactions.Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skinCanadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology.Effect of age and early intervention with a systemic steroid, intravenous immunoglobulin or amniotic membrane transplantation on the ocular outcomes of patients with Stevens-Johnson syndrome.The role of pharmacogenetics in treating central nervous system disorders.Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function.Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Immunological aspects of nonimmediate reactions to beta-lactam antibiotics.Animal models of toxic epidermal necrolysis.Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.Managing the challenge of chemically reactive metabolites in drug development.T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.Pharmacogenomics of adverse drug reactions: implementing personalized medicine.The generation, detection, and effects of reactive drug metabolites.Pediatric perspective on pharmacogenomics.Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality.
P2860
Q21202877-1D23A5AB-20CE-42EE-80D4-035D6344A00BQ26739886-1696EB89-3D6A-4103-BDF8-E87C04080939Q26800976-F9DF4D49-99EF-47C4-A09D-3E822EE5AA0BQ26824391-D9CB30E5-842E-4DDD-ACAB-53826E6370A2Q27335598-14A863BA-351D-4468-9108-F6BDE8EDE30AQ28074097-8A382ECE-B984-4819-AEA5-B84F962AC6D0Q28200201-E489F366-989B-4D59-964E-EA9551BA804EQ28483831-B23A5FD9-8DF1-4FEE-93CF-3C8F8E51CBACQ31122683-E4AD3984-2C2E-4229-A2AA-CD67C8A07887Q33777950-FDFD88E2-C717-40F0-B2E6-1E6745482760Q33788588-040D05FE-5E30-4F78-A7E4-94F8B85F7969Q34225850-404EDD48-04B2-4AA1-84AE-49E308F2B86FQ34239870-1447B522-16C5-4F57-955B-2ACC4C00041AQ34252093-0C124EBF-0388-4590-969D-4CC01FF40350Q34345953-2D5BCB21-550C-4BD1-B6A8-7CA2405D79BCQ34485108-489F2E15-0252-4011-9FCB-0EAA56CCC70CQ34496798-A5C712DA-45B8-4A3C-BE85-A5A1A2380FF3Q34609440-1DE5CE41-3AF5-4857-8DB0-389BF655658AQ34617803-FF91F14B-9CA9-4206-95DE-F6F65D9888A5Q34629177-CAD27C5D-3AAF-4692-ABBF-5A4679976BD0Q34742870-33432526-5823-457A-ABB4-F49F418C51AFQ34922937-A2B04B28-81E2-409E-8F07-070F4B96316AQ35004399-4795DE4D-0315-46B1-91F1-0EEBE046147CQ35132298-B24F2F8D-BFFB-4729-96EE-00DFF04360B5Q36439187-75BAE4F4-631B-4CB9-BAAC-538DEDDF1E66Q36440366-997E63C1-AE5C-422C-9FC3-05AEB8F1574DQ36711702-719EE89A-BF79-4079-8E6E-C7AA31852120Q37196161-DF9D8135-6DFA-414E-9FB3-3ABADE9F321DQ37292132-06DE9434-2C6B-4105-94B4-5407EB2D2E0FQ37633276-5011D4C2-F9D4-4B4C-935D-F968D4C3F47CQ37697237-1F4A3DEC-340A-4EFA-A248-B135ACF1BC4EQ37786631-3EBE2789-D3DF-42D6-8629-DF853F3C99DCQ37845915-9507D5C5-1FAF-48C1-BD10-3F13667619C2Q37853599-549B5FD4-BC59-4467-9086-87ECB86A2BC9Q37860142-AF2EF6E5-A02E-4634-8BA8-8F6E5306AF45Q38033651-57A5BCE9-B5C9-44E1-9EA2-873F61E2410EQ38036150-616EE6BD-E655-4460-990F-5ED4611506B8Q38054629-C24A0730-7A9E-432B-8F85-25A4E4E2A32CQ38162869-5C8729E8-2377-49DE-875A-9C3AD66AB8B1Q38235949-AEDD9535-3161-498E-A4AD-08E79E58FC1E
P2860
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.
@en
type
label
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.
@en
prefLabel
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.
@en
P2093
P1476
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells
@en
P2093
Amal Nassif
Aurelien Deniaud
Homayoun Moslehi
Jean-Claude Roujeau
Laurence Boumsell
Martine Bagot
Pierre Wolkenstein
P304
P356
10.1016/J.JACI.2004.07.047
P407
P577
2004-11-01T00:00:00Z